bluebird bio unveils US commercial strategy for LYFGENIA gene therapy
bluebird bio, Inc., a pioneer in the biotechnology industry, has announced the U.S. commercial infrastructure for LYFGENIA (lovotibeglogene autotemcel, also known as lovo-cel), an FDA-approved gene therapy for patients 12 years and older with sickle cell disease and a history of vaso-occlusive events (VOEs). The launch of LYFGENIA, leveraging bluebird’s experience in delivering ex vivo […]